Detalhe da pesquisa
1.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
N Engl J Med
; 390(4): 326-337, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38078508
2.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33428632
3.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910333
4.
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome.
Blood
; 137(26): 3676-3681, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33690815
5.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636043
6.
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.
Blood
; 125(12): 1932-5, 2015 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25645353
7.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Br J Haematol
; 193(3): e19-e22, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715154
8.
Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.
Blood
; 124(8): 1296-9, 2014 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24939658
9.
The clinical impact of staging bone marrow examination on treatment decisions and prognostic assessment of lymphoma patients.
Br J Haematol
; 170(2): 175-8, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25920510
10.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Br J Haematol
; 185(5): 948-951, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30460696
11.
Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK's Haematological Malignancy Research Network.
Cancer Epidemiol
; 88: 102513, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38160571
12.
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrom macroglobulinaemia.
Leukemia
; 38(4): 822-828, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38409530
13.
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
J Clin Oncol
; 41(23): 3945-3955, 2023 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315268
14.
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Lancet Haematol
; 10(2): e93-e106, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529145
15.
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
J Clin Oncol
; 40(25): 2889-2900, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35377708
16.
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.
BMJ Open
; 12(11): e063037, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36396306
17.
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.
BMJ Open
; 12(6): e056147, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654466
18.
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
N Engl J Med
; 359(6): 575-83, 2008 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-18687638
19.
Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies.
Histopathology
; 58(1): 90-105, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21261686
20.
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
Haematologica
; 101(2): e69-71, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26471484